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Abstract: Introduction: Stable patients with pulmonary arterial or chronic thromboembolic pulmonary
hypertension (PH) wish to undergo altitude sojourns or air travel but fear disease worsening. This pilot
study investigates health effects of altitude sojourns and potential benefits of nocturnal oxygen therapy
(NOT) in PH patients. Methods: Nine stable PH patients, age 65 (47; 71) years, 5 women, in NYHA class
II, on optimized medication, were investigated at 490 m and during two sojourns of 2 days/nights at 2,048
m, once using NOT, once placebo (ambient air), 3 L/min per nasal cannula, according to a randomized
crossover design with 2 weeks washout at <800 m. Assessments included safety, nocturnal pulse oximetry
(SpO2), 6-min walk distance (6 MWD), and echocardiography. Results: At 2,048 m, two of nine patients
required medical intervention, one for exercise-induced syncope, one for excessive nocturnal hypoxemia
(SpO2 < 75% for >30 min). Both recovered immediately with oxygen therapy. Two patients suffered
from acute mountain sickness. In 6 patients with complete data, nocturnal mean SpO2 and cyclic SpO2
dips reflecting sleep apnea significantly differed from 490 to 2,048 m with placebo, and 2,048 m with
NOT (medians, quartiles): SpO2 93 (91; 95)%, 89 (85; 90)%, 97 (95; 97)%; SpO2 dips 10.4/h (3.1; 26.9),
34.0/h (5.3; 81.3), 0.3/h (0.1; 2.3). 6 MWD at 490, 2,048 m without and with NOT was 620 m (563;
720), 583 m (467; 696), and 561 m (501; 688). Echocardiographic indices of heart function and PH were
unchanged at 2,048 m with/without NOT vs. 490 m. Conclusions: 7/9 PH patients stayed safely at
2,048 m but revealed hypoxemia, sleep apnea, and reduced 6 MWD. Hemodynamic changes were trivial.
NOT improved oxygenation and sleep apnea. The current pilot trial is important for designing further
studies on altitude tolerance of PH patients.
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Introduction: Stable patients with pulmonary arterial or chronic thromboembolic
pulmonary hypertension (PH) wish to undergo altitude sojourns or air travel but fear
disease worsening. This pilot study investigates health effects of altitude sojourns and
potential benefits of nocturnal oxygen therapy (NOT) in PH patients.
Methods: Nine stable PH patients, age 65 (47; 71) years, 5 women, in NYHA class
II, on optimized medication, were investigated at 490m and during two sojourns of 2
days/nights at 2,048m, once using NOT, once placebo (ambient air), 3 L/min per nasal
cannula, according to a randomized crossover design with 2 weeks washout at <800m.
Assessments included safety, nocturnal pulse oximetry (SpO2), 6-min walk distance
(6 MWD), and echocardiography.
Results: At 2,048m, two of nine patients required medical intervention, one for
exercise-induced syncope, one for excessive nocturnal hypoxemia (SpO2 < 75% for
>30min). Both recovered immediately with oxygen therapy. Two patients suffered from
acute mountain sickness. In 6 patients with complete data, nocturnal mean SpO2 and
cyclic SpO2 dips reflecting sleep apnea significantly differed from 490 to 2,048m with
placebo, and 2,048m with NOT (medians, quartiles): SpO2 93 (91; 95)%, 89 (85; 90)%,
97 (95; 97)%; SpO2 dips 10.4/h (3.1; 26.9), 34.0/h (5.3; 81.3), 0.3/h (0.1; 2.3). 6 MWD
at 490, 2,048m without and with NOT was 620m (563; 720), 583m (467; 696), and
561m (501; 688). Echocardiographic indices of heart function and PH were unchanged
at 2,048m with/without NOT vs. 490 m.
Conclusions: 7/9 PH patients stayed safely at 2,048m but revealed hypoxemia,
sleep apnea, and reduced 6 MWD. Hemodynamic changes were trivial. NOT improved
oxygenation and sleep apnea. The current pilot trial is important for designing further
studies on altitude tolerance of PH patients.
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INTRODUCTION
Precapillary pulmonary hypertension (PH) is defined as mean
pulmonary artery pressure (PAP) > 20 mmHg and pulmonary
artery wedge pressure (PAWP) ≤ 15 mmHg along with a
pulmonary vascular resistance (PVR) ≥ 3 WU assessed by right
heart catheterization (1). Since 1998, PH has been classified
into five major groups according to clinical presentation and
response to vasodilator and antiproliferative therapies (1). In
FIGURE 1 | Patient flow. OSAS, obstructive sleep apnea syndrome; CVI, cerebrovascular insult.
the absence of predominant lung or certain rare diseases, the
major precapillary PH forms are pulmonary arterial hypertension
(PAH) and chronic thromboembolic PH (CTEPH), defined as
groups I and IV and below summarized as PH and these groups
are also summarized as pulmonary vascular diseases (PVD)
(1). The leading symptom in PH is dyspnea on exertion with
impaired exercise performance and restrained daily activity (2).
With progression of the disease, worsening hemodynamics may
lead to gas exchange disturbances associated with hypoxemia,
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particularly during exercise and sleep (3, 4). Current guidelines
recommend that PH patients with hypoxemia or exertional
dyspnea or in New York Heart Association functional class ≥III
avoid traveling to altitudes above>1,500m and use supplemental
oxygen during air travel (5). However, these recommendations
are not based on scientific evidence. In a recent review of
the literature, no conclusive studies regarding the effect of a
hypoxic environment at altitude on patients with preexisting
PH was found (6). A nonrandomized small study in patients
with PAH exposed for 20min to normobaric hypoxia with an
inspiratory oxygen fraction (FiO2) of 15% corresponding to
an altitude of ≈2,500m revealed that resting PAP assessed by
echocardiography did not increase (7). Moreover, we recently
showed that exposure to normobaric hypoxia (FiO2 15%) during
right heart catheterization did not significantly change invasive
pulmonary hemodynamics at rest in patients with PAH/CTEPH
despite a decrease in arterial oxygen tension from 9.5 to
7.0 kPa (8). It is not known whether and to what extent
environmental hypoxia during hours to days as in air travel or
altitude sojourns is harmful for patients with PH, and potential
risk factors are not identified. In our previous short-duration
study with normobaric hypoxia, PH patients revealed an even
smaller fall in arterial oxygen tension compared to unaffected
controls while breathing hypoxia during 15′, related to increased
hyperventilation as indicated by the significant decrease in
arterial partial pressure of carbon dioxide (PaCO2) (8). In healthy
volunteers, exercise performance is gradually impaired with
increasing hypoxia/altitude (9) and even more in patients with
COPD (10, 11) and improves with adaptation (12). Data on PH
patients exercising at altitude is completely lacking.
Worldwide, millions of people travel regularly to higher
settlements or mountain areas for business or recreational
purposes and expose themselves to hypobaric hypoxia during
days to weeks or even longer. In addition, traveling by airplane,
which has become extremely popular, further increased the
number of people that are transiently exposed to a hypoxic
environment, as the lower limit of cabin pressure is equivalent
to 2,430m (8,000 ft) of altitude. Very little is known about
the cardiovascular adaptive changes and risks during exposure
to hypoxia in PH patients. In our daily practice, many PH
patients ask whether they can travel with their relatives and
friends to the nearby Alps or undergo air travel for business or
recreational purposes.
Therefore, the purpose of the current pilot trial in PH patients
was to evaluate safety, echocardiographic indices of cardiac
function, exercise performance, and sleep-related breathing
disturbances during a stay at moderately high altitude and to
evaluate the hypothesis that nocturnal oxygen therapy (NOT)
during the altitude sojourn would improve these outcomes.
MATERIALS AND METHODS
Study Design
This randomized, placebo-controlled, blinded crossover pilot
trial was performed from January to October 2014, in PH
patients permanently living <800m. The study was approved
by the Cantonal Ethics Committee Zurich (EK-2013-0088), and
TABLE 1 | Baseline characteristics given as median (IQR) or number (%).
N 6
Sex, male/female 3/3
Age 65 (49; 71)
Body mass index, kg/m2 24.4 (23.7; 26.8)
New York Heart Association functional class II 6 (100)
6-minute walking distance, m 620 (562; 720)
Pulmonary hypertension group
Pulmonary arterial hypertension 2 (33)
Chronic thromboembolic pulmonary hypertension 4 (67)
Right heart catheter
Mean pulmonary artery pressure, mmHg 36 (30; 43)
Pulmonary artery wedge pressure, mmHg 10 (9–10)
Pulmonary vascular resistance, WU 5.9 (5.2; 9.0)
Cardiac index, L·min−1·m−2 2.2 (2.0; 2.4)
Pulmonary hypertension treatment
Endothelin receptor antagonist 3 (50)
Phosphodiesterase-5 inhibitors 2 (33)
Combination therapy 1 (17)
Calcium channel blockers 1 (17)
PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial pressure of
carbon dioxide.
all participants signed a written informed consent. The trial is
registered at clinicaltrials.gov, NCT02150616.
It evaluated the effects of NOT vs. placebo (nocturnal
ambient air) during two sojourns at 2,048m on symptoms,
safety, sleep disordered breathing (SDB), vital signs, exercise
performance, and hemodynamics by echocardiography.
Participants underwent baseline evaluations during daytime and
an overnight stay at 490m (Zurich, Switzerland) and had the
same evaluations over the course of 2 sojourns of 2 days/nights
each in a mountain hotel at 2,048m (St. Moritz, Switzerland).
During the nights at 2,048m, patients received either NOT or
placebo (3 l/min) according to a randomized crossover trial via
a nasal cannula. To minimize carryover effects, patients had to
spend at least 2 weeks at low altitude (<800m) between the two
altitude sojourns.
Patients
Patients with pulmonary arterial or chronic thromboembolic PH
living below 800m in New York Heart Association functional
class II–III were recruited at the University Hospital of Zurich.
Patients with unstable or exacerbated condition, severe
PH (functional class IV), concomitant unstable cardiovascular
disease, hypoventilation, severe hypoxemia needing long-
term oxygen therapy at low altitude or drugs that affect
respiratory center drive, previous intolerance of moderate
altitude (<2,600m), or exposure to altitudes >1,500m for >2
days within the last 4 weeks before the study were excluded.
Randomization
Patients were randomized to receive either NOT or nocturnal
placebo (ambient air) at altitude. Participants traveled by train
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St. Moritz 2048 m
Placebo
n = 6
St. Moritz 2048 m NOT
n = 6
Day 1 Day 2 Day 1 Day 2
Vital signs
HR rest, 1/min 64 (56; 78) 66 (61; 77) 71 (65; 76) 70 (64; 72) 70 (62; 78)
BP rest, systolic, mmHg 114 (102; 142) 127 (121; 135) 127 (121; 135) 125 (117; 132) 121 (113; 141)
BP rest, diastolic, mmHg 74 (71; 89) 80 (72; 89) 80 (72; 88) 78 (71; 82) 76 (69; 89)
SpO2 pre 6 MWD, % 97 (94; 98) 95 (88; 96)* 95 (92; 95) 95 (90; 97) 95 (90; 95)
6-minute walk test
6 MWD, m 620 (563; 720) 583 (467; 696)* 563 (485; 653)* 561 (501; 688)* 572 (500; 691)*
HR end 6 MWD, 1/min 94 (80; 106) 104 (95; 123)* 103 (84; 116) 100 (95; 116)* 108 (97; 149)*
BP end 6 MWD, systolic, mmHg 150 (146; 155) 175 (171; 186)* 177 (170; 183)* 175 (170; 191)* 173 (153; 197)
BP end 6 MWD, diastolic, mmHg 86 (77; 96) 93 (85; 100) 89 (79; 97) 83 (72; 119) 84 (72; 95)
SpO2 end 6 MWD, % 87 (82; 92) 83 (76; 87)* 80 (73; 87) 78 (69; 83)
# 80 (75; 87)
Borg dyspnea 3.5 (1.6; 5.0) 4.5 (3.0; 7.2) 5.0 (3.0; 5.8)* 4.5 (3.0; 6.0) 4.5 (3.0; 7.8)
Borg fatigue 2.5 (0.8; 4.5) 5.0 (2.3; 7.0)* 5.0 (2.3; 5.3) 3.0 (2.3; 4.8) 4.0 (2.3; 6.0)
Constant work-rate endurance test (CWRET) at 60% of Wmax
Endurance time, s 826 (243; 1410) 200(160; 785)* 424 (163; 694)
PaO2 end CWRET, mmHg 59.7 (51.6; 67.4) 53.9 (43.9; 63.9) 54.6 (42.2; 60.7)
SaO2 end CWRET, % 90.8 (87.1; 94.1) 83.3 (75.2; 91.7) 89.5 (75.7; 91.4)
Arterial blood gas analysis
pH 7.48 (7.42; 7.48) 7.46 (7.44; 7.49) 7.46 (7.48; 7.49)
PaO2, mmHg 65 (60; 72) 60 (54; 63) 58(50; 61)*
PaCO2, mmHg 32 (29–35) 32 (29–34) 33 (29–36)
Sleep study
SpO2, % 93 (91; 95) 89 (85; 90)* 90 (89; 92)* 97 (95; 97)*
# 97 (95; 97)* #
ODI, 1/h 10.4 (3.1; 26.9) 34.0 (5.3; 81.3)* 27.2 (6.9; 61.5)* 0.3 (0.1; 2.3)* # 0.7 (0.1; 4.0)* #
AHI, 1/h 27.3 (17.5; 38.7) 34.2 (13.3; 71.2) 29.8 (16.5; 63.7) 23.9 (2.4; 30.7) 15.2 (7.7; 33.0)*#
HR, heart rate; BP, blood pressure; 6 MWD, 6-minute walking distance; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial pressure of carbon dioxide; SpO2, oxygen
saturation; ODI, oxygen desaturation index; AHI, apnea/hypopnea index. *Significant difference to low altitude baseline p < 0.05; #significant difference to placebo of the same
night p < 0.05.
and car within 3 h from 490m to 2,048m. Between altitude
sojourns, a >2-week washout period <800m was imposed.
Intervention
Patients received NOT or placebo (ambient air) during nights at
2,048m provided via nasal prongs connected to a concentrator
(EverFlo, Philips Respironics, Zofingen, Switzerland) with a
constant flow rate of 3 l/min. Patients were blinded for the
intervention by placing the concentrators in a separate room.
For safety reasons, SpO2 was permanently monitored by
the investigators at night and patients received oxygen, when
SpO2 was <75% for more than 30min during the sojourn
at 2,048m altitude or in the presence of symptoms requiring
an intervention.
Assessments
All symptoms, sings, or events relevant for safety and/or
requiring medical intervention were noted, in particular
excessive hypoxemia (SpO2 < 75% for > 30min) and acute
mountain sickness (AMS), among others.
AMS was evaluated with the Environmental Symptoms
Questionnaire cerebral score (AMSc). AMSc scores ≥ 0.7 were
considered to be clinically relevant AMS (13).
The 6-min walking test was performed according to guidelines
(14). Arterial blood gases were obtained at low altitude and at
high altitude after the 1st night.
Patients performed an incremental (ramp) exercise test on
arrival (before NOT resp. placebo) and a constant work-rate
exercise test on day 2 during each sojourn (60% of the maximal
work rate achieved in the incremental work-rate test at lowland).
Echocardiography was performed in Zurich and on day
2 (after the first night) at altitude according to previously
published studies and included assessments of right ventricular
function (right ventricular fractional area change (RV-FAC),
tricuspid annular plane systolic excursion (TAPSE), and peak
systolic right ventricular to right atrial pressure gradient (RV/RA
gradient) (15). Echocardiographic recordings were performed
with a real-time, phased array sector scanner (CX 50, Philips,
Philips Respironics, Zofingen, Switzerland) with an integrated
Color Doppler system and a transducer containing crystal sets
Frontiers in Medicine | www.frontiersin.org 4 September 2020 | Volume 7 | Article 502
Lichtblau et al. Altitude and NOT in PH
FIGURE 2 | Six-minute walking distance (6 MWD) and oxygen saturation
(SpO2) at the beginning and end of the 6 MWD of the patients who completed
the study. Bold, median.
for imaging (1–5 MHz) and for continuous-wave Doppler.
Measurements were carried out according to guidelines of the
European Association of Echocardiography (16).
Patients had a respiratory sleep study (Alice 5, Philips
Respironics) according to international standards (17, 18) at
low and high altitude. Apneas/hypopneas were scored when
there was a reduction of nasal pressure swings or the inductive
plethysmographic sum signal to <50% of baseline for >10 s, as
described previously (19–21) (Transient reductions in breathing
amplitude to <50% of baseline for 5–10 s were also scored
as apneas/hypopneas if they occurred as part of a periodic
breathing pattern with hyperventilation alternating with central
apneas/hypopneas for at least three consecutive cycles.). The
apnea/hypopnea index (AHI) was computed as the number of
events per hour of total sleep time and time in bed; the oxygen
desaturation index (ODI, > 3% SpO2 dips) was computed as
the number of events per hour of time in bed as described
previously (22).
Outcomes
Main endpoints were safety and tolerability of altitude exposure,
blood oxygenation (SpO2 and blood gases), exercise performance
(6-min walking distance (6 MWD), cycle endurance time),
hemodynamics/heart function by echocardiography, sleep-
related breathing disturbances, and the effect of NOT on
these parameters.
Statistics
In this pilot study, measurements are presented for each patient
separately and/or summarized for the six patients who were
treated by protocol as median and quartiles. Comparisons
between summarized measures were performed with the
Wilcoxon test. P < 0.05 was considered as a statistically
significant difference; all analyses were performed with the
statistical program SPSS 25 (SPSS, Chicago, IL, USA).
RESULTS
Nine patients with PH were included in the study with a median
age of 65 (49; 71) years, 5 women, and 5 CTEPH/4 PAH, all in
NYHA functional class II; the study flow is presented in Figure 1.
Baseline characteristics of the six patients who completed the
study are shown in Table 1.
One patient fulfilled the predefined safety criterion of SpO2
<75% for more than 30min during the sojourn at 2,048m during
the placebo phase and was treated with oxygen accordingly
(Patient ID 2). Two other patients performed only one visit at
altitude and therefore did not complete the protocol: one was
due to personal reasons (Patient ID 4), and the other patient
had a syncope during cardiopulmonary exercise testing the day
of arrival (Patient ID 9). This patient and the other one suffered
from AMS (Patient ID 9 and 6). Six patients completed the study
procedure according to the protocol.
The arterial partial pressure of oxygen (PaO2) assessed by
arterial blood gases was significantly lower only after the 1st
night with NOT compared to the low altitude baseline, but
not compared to placebo, and PaO2 after placebo was similar
to low altitude measures. PaCO2 did not significantly differ in
all circumstances (see Table 2). Heart rate and systolic blood
pressure at the end of 6 MWD were significantly higher at
altitude, irrespective of the intervention (see Table 2).
All patients had a reduced 6 MWD at 2,048m compared
to 490m. Patients desaturated during 6 MWD in all phases.
The lowest SpO2 was found at the end of 6 MWD at 2,048m
after receiving NOT, and between-group difference was only
significant comparing desaturation at 490 vs. 2,048m after having
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TABLE 3 | Echocardiographic measures of all patients listed separately and median (IQR) for n = 6 who performed the study according to protocol.



























1 25 21 24 2.2 2.7 2.4 53 46 43
3 43 29 42 2 1.4 1.7 22 24 25
5 37 44 47 2.8 2.5 2.7 10 21 16
6 39 43 30 2.7 2.4 2.19 53 77 68
7 32 48 40 2.2 2.3 3.4 17 19 31
8 41 37 38 2.3 2.2 2.5 26 22 38
Median (IQR) 38 (30–41) 40 (27; 46) 39 (29; 43) 2.3 (2.2; 2.7) 2.4 (2.0; 2.5) 2.4 (2.1; 2.9) 24 (15; 53) 24 (20; 54) 35 (22; 49)
2 30 34† 40 1.6 2.0† 2.2 28 40† 41
4 33 36 2.3 2.8 22 23
9 33 1.8 86
RV, right ventricle; FAC, fractional area change; TAPSE, tricuspid annular plane systolic excursion; RA, right atrium; NOT, nocturnal oxygen therapy.
†
Patient received NOT in the placebo
phase due to hypoxemia.
received NOT (p = 0.043), but not placebo, shown in Table 2
and Figure 2. Constant work-rate cycle endurance time was
significantly reduced at altitude when patients received placebo, p
= 0.046 (Table 2). All patients performed an incremental exercise
test at lowland and shortly after arrival at altitude; however,
the difference was not statistically significant (490 vs. 2,048m
(placebo): 109 (83; 201) vs. 103 (77; 187) W, p= ns).
Echocardiographic measures did not reveal significant
differences between low and high altitude and between altitude
sojourns with and without NOT (see Table 3).
Altitude induced a significant decrease in nocturnal SpO2 and
increase in ODI during both nights of the sojourn under placebo.
AHI did not change significantly but tended to be higher at
altitude. NOT at altitude significantly increased nocturnal SpO2
and decreasedODI andAHI compared to lowland and evenmore
to altitude sojourns without NOT (Table 2 and Figure 3).
DISCUSSION
We performed a randomized, placebo-controlled, single-blind,
crossover pilot trial to evaluate the effect of an altitude
sojourn with and without NOT on safety and tolerability,
blood oxygenation, exercise performance, hemodynamics, and
SDB in patients with PH staying for 2 days and nights
at moderate altitude (2,048m). Exposure to altitude induced
arterial hypoxemia and reduction of exercise performance,
along with higher heart rates and blood pressures at end of
exercise and increase in SDB. NOT improved SDB but not
daytime exercise performance. Right heart function measured
by echocardiography revealed no significant changes at altitude
with or without NOT. Out of 9 patients, two had altitude-related
adverse health effects, one patient needed oxygen, and another
one had a syncope during cardiopulmonary exercise testing on
the day of arrival. The latter patient and another one fulfilled
criteria for AMS according to the AMSc questionnaire.
Clinical data and particularly randomized-controlled trials on
patients with cardiorespiratory disorders, such as heart failure
(HF) or COPD, traveling at altitude is scarce, and no data are
available for patients with PH (6). In HF, altitude exposure is
not recommended if patients are unstable (23) or suffer from
comorbidities that may directly interfere with the adaptation to
altitude (24). Only few studies are available in clinically stable
patients with HF on optimal medical treatment investigating
short exposure to real altitude or normobaric hypoxia simulating
altitude near sea level (24, 25). One of those studies assessed
exercise capacity in 29 optimally treated and stable patients
with severe HF [ejection fraction < 40%, peak oxygen uptake
(peak VO2) > 50% predicted] traveling to 3,454m (4–5-h stay
at altitude) and revealed a reduction of 22.2% in the peak VO2
(26). Another study revealed no increase in the number of
cardiac events in patients with coronary artery disease or HF with
preserved ejection fraction exposed up to 3,500m (23, 27, 28).
Wyss et al. investigated patients with coronary artery disease
under normobaric hypoxia (FiO2 15%, equivalent to ∼2,500m)
and found a decreased coronary flow reserve assessed by positron
emission tomography on exercise (25).
Forty patients with moderate to severe COPD (median FEV1
59% predicted) have been assessed in a randomized crossover
trial ascending to 2,590m, and a 24% incidence of altitude-
related adverse health effects was reported, confirming the
increased susceptibility in COPD patients exposed to moderate
hypobaric hypoxia (29). In the same trial, left and right heart
function was assessed by echocardiography, revealing an increase
in pulmonary artery pressure and slight reduction in right
ventricular function as well as an increase in diastolic dysfunction
at altitude (15). At such altitudes, adverse events requiring
medical treatment or descent have not been reported in healthy
volunteers or in patients with obstructive sleep apnea syndrome
(30, 31).
COPD guidelines recommend in-flight oxygen in patients
with severe COPD when the hypoxic altitude simulation test
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FIGURE 3 | Sleep study results of the patients who completed the study are
shown. SpO2, oxygen saturation; ODI, oxygen desaturation index; AHI,
apnea/hypopnea index; Bold, median.
reveals PaO2 < 50 mmHg or SpO2 < 85% (32). However,
the role of this hypoxia-altitude-simulating test has never been
established, as the degree of deoxygenation during the test hast
not been shown to predict symptoms at real altitude (33). In
line with this, a currently published trial has shown that 16%
of moderate to severe COPD patients, who did not fulfill the
criteria to perform a hypoxia-altitude simulation test, revealed
severe deoxygenation at 2,048m of real altitude (22).
Our study is the first to investigate lowlanders with stable
but symptomatic PH during a 2-day/night altitude sojourn.
We found that out of nine patients, two (22%) experienced
altitude-related adverse health events, one severe nocturnal
oxygen desaturation, the other exertional syncope, and two
(22.2 %) fulfilled the diagnostic criteria of AMS, but these
two did not need additional treatment. Despite the fact that
altitude exposure was associated with a significantly lower blood
oxygenation, pulmonary hemodynamics by echocardiography
was not significantly different and also not altered with NOT
at altitude. Similarly, no significant changes in right ventricular
systolic function were found in our PH cohort. The patient
number in this pilot study was too small to detect minor
changes, but major hemodynamic decompensation was not
observed. In a previous study in PH patients assessed during
short-term exposure to normobaric hypoxia during right heart
catheterization (15min, FiO2 15%), we also found that the
pulmonary vascular resistance was similar to ambient air
breathing. In accordance with healthy volunteers and patients
with cardiovascular diseases or COPD, exercise performance
as assessed by the 6 MWD was reduced at altitude and
irrespective of whether NOT or placebo were applied during the
nights (11, 24).
We and others have demonstrated that SDB including
nocturnal oxygen desaturation and periodic breathing are highly
prevalent in patients with right heart failure due to PH of
various etiologies and are associated with reduced quality of
life, impaired exercise capacity, and hemodynamics (3, 34–36):
39% of 43 PH patients studied at our center had ≥ 10 events/h
of Cheyne–Stokes respiration/central sleep apnea (CSR/CSA),
and the majority of them (68%) spent more than 10% of
the night time with a low arterial SpO2 (<90%). With the
current study, we have shown that SDB in PH are even more
pronounced at altitude. This is in line with healthy volunteers,
patients with COPD, and highlanders permanently living above
2,600 m (29, 37, 38).
This trial included only stable PH patients in NYHA class
II; therefore, this data may not apply to more severe PH
patients, at higher altitudes or longer exposures. Patients which
were included in this trial were relatively physically fit (median
baseline 6 MWD 620m at 490m). How PH patients with worse
exercise performance at low altitude would tolerate altitude with
and without NOT remains to be studied. The sample size of 6
was too small to draw definitive conclusions on outcomes and to
detect significant changes in pulmonary artery pressure and right
heart function with altitude. However, this was an exploratory
pilot study that paved the way to future larger trials.
CONCLUSION
In conclusion, 7 of 9 stable PH patients were able to safely
travel to 2,048m. One patient suffered from syncope during
maximal incremental exercise test and another from low oxygen
saturation over a sustained period of time during the night
needing oxygen therapy. Altitude exposure induced hypoxemia,
impairment of exercise performance, and SDB. NOT improved
SDB but had no sustained effect on exercise performance or
echocardiographic parameters during daytime. Our pilot trial is
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an important basis for designing further trials evaluating altitude
tolerance of PH patients.
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